Navigation Links
Drop Patent Petition, Activists Ask Novartis

Seeking to keep the price of a cancer drug affordable for masses, activists from several countries Monday gathered here and asked Swiss pharmaceutical major Novartis// to withdraw its case against the Indian government that has not granted patent to its anti-cancer medicine.

"India produces affordable medicines that help millions of people both here and in many other developing countries. A patent grant to Novartis on Gleevec will certainly make cancer medicine unaffordable for the poor," said Amit Sengupta, joint convenor of the PEOPLE'S Health Movement.

"While a generic drug for cancer costs Rs.8,000 for one month of treatment, Gleevec costs Rs.120,000. If Novartis gets the patent, then generic drugs will not be available in market," Sengupta told reporters.

In May 2006, Novartis had filed two cases against the government of India and the Cancer Patients Aid Association (CPAA) challenging the rejection of its patent application under the Indian Patent Law.

The company's application for a patent on Gleevec was opposed by the CPAA and subsequently rejected by the Chennai patent office in January 2006.

The application was rejected as it claimed Gleevec to be only a new form of an old drug and not an invention.

Unni Karunakara, medical director of the Medicins Sans Frontieres, a Netherlands-headquartered organisation, said that India is the main supplier of essential medicines for developing countries. Sixty-seven percent of the medicines produced in India are exported to developing countries, he said.

"A patent grant to Novartis will not only affect people in India but also millions of people in developing countries. It will set a wrong precedent for frivolous applicants to get patent by just tinkering molecules. Innovations of drugs will become difficult," Karunakara said.

"General public cannot afford the second line drugs as their cost will increase between seven to 30 times, " he added.

Michel Lotrowski, a Brazilian activist, said Novartis was embarking on sheer profiteering without even thinking of public health conditions.

K.M. Gopakumar, a member of the Centre for Trade and Development, said Novartis had challenged Section 3-D of the Indian Patent Act that dismisses frivolous patent applications as incongruous.

"Does the multinational want to say that the Indian government should frame law keeping in mind Novartis' profit motive? Can't we stop frivolous patent applications from seeing light?" Gopakumar asked.

Source-IANS
'"/>




Related medicine news :

1. Indian Government Keen On JE Vaccine Supply And Patenting Of Indian Medicine Formulations
2. HIV Patients Opposes Patenting Of AIDS Drug
3. Provigil Patent Extension Accorded To Cephalon
4. AIDS Sufferers Protest against Proposed Patent for Tenofovir
5. POLY Medicure Ltd Applies for 8 Patents, 2 FDA Approvals
6. Venus Remedies Files 5th International Patent Application
7. US Court Rules Against Lupin in Ramipril Patent Case
8. Patent for Seminal RNAi innovation Cleared in Australia
9. Canada: On Popular Demand, Tamiflu finds a Berth in the Directory of Patent Drugs
10. Compellis Pharmaceuticals Gets Patent for Obesity-Fighting Nasal Spray CP404
11. A Patented Device for Rapid Diagnosis of Diseases
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/9/2016)... - Cincinnati, Ohio (PRWEB) , ... December 09, ... ... the production of miniature, folded, pharmaceutical inserts and outserts. As a means ... Device. This addition will enable Flottman to individually code professional inserts (PIs) ...
(Date:12/9/2016)... ... December 09, 2016 , ... An inventor from Cana, Va., wanted to fulfill ... of amusement park rides. , The patent-pending SAFETY STRAP FOR AMPUTEES improves accessibility. It ... could be set up in a matter of minutes, or even seconds. The SAFETY ...
(Date:12/9/2016)... , ... December 09, 2016 , ... "I had a ... inventor from Winchester, Va. "I thought that if the nebulizer had a more child-friendly ... than fearing them." , He developed the patent-pending NEBY to avoid the need to ...
(Date:12/8/2016)... , ... December 08, 2016 , ... ... Research Institute (WCRI) officially opened registration today for its 33rd Annual Issues ... Boston, MA . , The theme of the conference is “Persistent Challenges and ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... Management (MTM), adherence, and other pharmacist-delivered patient care services, has announced the promotions ... Eric Hoessel to vice president of sales. , Litsinger joined Mirixa in ...
Breaking Medicine News(10 mins):
(Date:12/9/2016)... , Dec. 9, 2016  RxWiki Inc., a digital ... digital marketing strategies of thousands of pharmacies through its ... Austin Inno,s "50 on Fire" Award in ... "We,re pleased to accept the award as one of ... Chief Executive Officer at RxWiki. "Our platform gives independent ...
(Date:12/8/2016)... , Dec. 8, 2016 IRIDEX Corporation (NASDAQ: ... newly issued shares of common stock, $0.01 par value (the ... underwritten public offering.  The final terms of the Offering will ... pricing, and there can be no assurance as to whether ... expects to use the net proceeds it will receive from ...
(Date:12/8/2016)... , Dec. 8, 2016 Global Interventional ... on the global interventional radiology market analyzes the ... report comprises an elaborate executive summary, including a ... segments and sub-segments. The research is a ... formed the bulk of our research efforts along ...
Breaking Medicine Technology: